1
|
Losi P, Barsotti MC, Foffa I, Buscemi M, De Almeida CV, Fabbri M, Gabbriellini S, Nocchi F, Ursino S, Urciuoli P, Mazzoni A, Soldani G. In vitro human cord blood platelet lysate characterisation with potential application in wound healing. Int Wound J 2019; 17:65-72. [PMID: 31665826 DOI: 10.1111/iwj.13233] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 09/06/2019] [Accepted: 09/13/2019] [Indexed: 01/19/2023] Open
Abstract
Platelets contain abundant growth factors and cytokines that have a positive influence on the migration and proliferation of different cell types by modulating its physiopathological processes. As it is known that human umbilical cord blood platelet lysate (UCB-PL) contains a supraphysiological concentration of growth factors, in the present study, we investigated its effectiveness in wound-healing processes. Human UCB-PL was obtained by the freeze/thaw of platelet concentrate (1.1 × 109 platelets/L), and its effect was evaluated on human or mouse endothelial cells, monocytes, fibroblasts, and keratinocytes in different concentrations. Human UCB-PL was observed to have high levels of pro-angiogenic growth factor than peripheral blood platelet-rich plasma. Among the cell lines, different concentrations of human UCB-PL were necessary to influence their viability and proliferation. For L929 cells, 5% of total volume was necessary, while for human umbilical vein endothelial cell, it was 10%. Cell migration on monocytes was increased with respect to the positive control, and scratch closure on keratinocytes was increased with respect to serum-free medium with only 10% of human UCB-PL. We concluded that the human UCB-PL may be useful to produce a large amount of standard platelet concentrates sufficient for several clinical-scale expansions avoiding inter-individual variability, which can also be used as a functional tool for clinical regenerative application for wound healing.
Collapse
Affiliation(s)
- Paola Losi
- Laboratorio di Medicina Rigenerativa, Biomateriali e terapie avanzate, Institute of Clinical Physiology, National Research Council, Massa, Italy
| | - Maria C Barsotti
- Laboratorio di Medicina Rigenerativa, Biomateriali e terapie avanzate, Institute of Clinical Physiology, National Research Council, Massa, Italy
| | - Ilenia Foffa
- Laboratorio di Medicina Rigenerativa, Biomateriali e terapie avanzate, Institute of Clinical Physiology, National Research Council, Massa, Italy
| | - Marianna Buscemi
- Laboratorio di Medicina Rigenerativa, Biomateriali e terapie avanzate, Institute of Clinical Physiology, National Research Council, Massa, Italy
| | - Carolina V De Almeida
- Laboratorio di Medicina Rigenerativa, Biomateriali e terapie avanzate, Institute of Clinical Physiology, National Research Council, Massa, Italy
| | - Marco Fabbri
- Laboratorio di Immunogenetica, Medicina Trasfusionale e Biologia dei Trapianti, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Sabrina Gabbriellini
- Laboratorio di Immunogenetica, Medicina Trasfusionale e Biologia dei Trapianti, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Francesca Nocchi
- Laboratorio di Immunogenetica, Medicina Trasfusionale e Biologia dei Trapianti, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Silvia Ursino
- Laboratorio di Immunogenetica, Medicina Trasfusionale e Biologia dei Trapianti, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Patrizia Urciuoli
- Laboratorio di Immunogenetica, Medicina Trasfusionale e Biologia dei Trapianti, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Alessandro Mazzoni
- Medicina Trasfusionale e Biologia dei Trapianti, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Giorgio Soldani
- Laboratorio di Medicina Rigenerativa, Biomateriali e terapie avanzate, Institute of Clinical Physiology, National Research Council, Massa, Italy
| |
Collapse
|
2
|
Mousavi SH, Abroun S, Zarrabi M, Ahmadipanah M. The effect of maternal and infant factors on cord blood yield. Pediatr Blood Cancer 2017; 64. [PMID: 27905684 DOI: 10.1002/pbc.26381] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2016] [Revised: 11/05/2016] [Accepted: 11/07/2016] [Indexed: 11/11/2022]
Abstract
Umbilical cord blood (CB) can be used as an alternative hematopoietic stem cell source for transplantation in hematological malignancy and blood disorders. The success of transplantation is highly related to the levels of total nucleated cell and CD34+ cell counts. The evaluation of optimal conditions can decrease the rate of graft rejection due to low cell count and increases the quality of CB units (CBUs) in the blood bank and the success rate of engraftment. To this end, we review the maternal and infant parameters affecting the quality and quantity of CBUs.
Collapse
Affiliation(s)
- Seyed Hadi Mousavi
- Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
| | - Saeid Abroun
- Department of Hematology, School of Medical Sciences, Tarbiat Modarres University, Tehran, Iran
| | - Morteza Zarrabi
- Royan Stem Cell Technology Institute, Cord Blood Bank, Tehran, Iran
| | - Mona Ahmadipanah
- Royan Stem Cell Technology Institute, Cord Blood Bank, Tehran, Iran
| |
Collapse
|
3
|
Screnci M, Murgi E, Tamburini A, Pecci MR, Ballatore G, Cusanno A, Valle V, Luciani P, Corona F, Girelli G. Family directed umbilical cord blood banking for acute leukemia: usage rate in hematopoietic stem cell transplantation. Stem Cell Rev Rep 2016; 11:275-9. [PMID: 25504378 DOI: 10.1007/s12015-014-9579-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Family-directed umbilical cord blood (UCB) collection and banking is indicated in women delivering healthy babies who already have a member of their own family with a disease potentially treatable with an allogeneic hematopoietic stem cell (HSCs) transplantation (HSCT). The rapid availability of UCB is an important issue in HSCs procurement particularly for recipients with acute leukemia who urgently need HSCT. The aims of this study were to assess the usage rate of family UCB collections directed to patients with acute leukemia and to investigate the factors influencing the usage rate. A total of 113 families were enrolled, 118 UCB units were successfully collected and one collection failed due to emergency occurred during delivery. Among these, 7 collections were required for children who were in urgent need of a transplant: three HLA-matched units were successfully transplanted, respectively after 2, 5 and 6 months from collection; three collections resulted HLA-mismatched, while HLA-typing is pending for one unit. The remaining collections were mostly required for potential future use, among these units only one was transplanted in a HLA compatible sibling after 3 years and 4 months from collection. After a median time of storage of 8.5 years (range 0.1-20 years) a total of 4/118 (3.4 %) collection has been transplanted. During this time interval, considering only patients who have had the need of a transplant, the main factor influencing low utilization rate of UCB collections was due to HLA disparity, indeed among typed UCB unit mostly (77 %) resulted HLA mismatched with the intended recipient.
Collapse
Affiliation(s)
- M Screnci
- Department of Immunoematologia e Medicina Trasfusionale, Azienda Policlinico Umberto I, Via Chieti N°7, 00161, Rome, Italy,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Effects of obstetric factors and storage temperatures on the yield of endothelial colony forming cells from umbilical cord blood. Angiogenesis 2011; 14:381-92. [PMID: 21720855 PMCID: PMC3155043 DOI: 10.1007/s10456-011-9222-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2011] [Accepted: 06/16/2011] [Indexed: 11/08/2022]
Abstract
As umbilical cord blood (UCB) is a rich source of endothelial colony-forming cells (ECFC), our aim was twofold: (1) to examine potential obstetric selection criteria for achieving the highest ECFC yields from UCB units, and (2) to determine whether transient storage temperatures of fresh UCB and cryopreservation of UCB units affected ECFC yield and function. ECFC quality was assessed before and after cryopreservation by their clonogenic proliferative potential. Of the 20 factors examined, placental weight was the only statistically significant obstetric factor that predicted ECFC frequency in UCB. Studies on the effects of storage revealed that transient storage of fresh UCB at 4°C reduced ECFC yield compared with storage at 22°C, while cryopreservation of UCB MNCs significantly reduced ECFC recoveries. To our knowledge, this is the first demonstration that placental weight and temperature of storage prior to processing or culture have significant effects on ECFC frequency in UCB. Our studies further support the evidence that cryopreservation of UCB MNCs compromises ECFC recovery.
Collapse
|
5
|
Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood 2010; 116:1849-56. [PMID: 20538797 DOI: 10.1182/blood-2010-02-271692] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
We analyzed risk factors influencing outcomes after related (R) human leukocyte antigen-identical cord blood transplantation (CBT) for 147 patients with malignancies reported to Eurocord-European Group for Blood and Marrow Transplantation. CBT has been performed since 1990; median follow-up was 6.7 years. Median patient age was 5 years. Acute leukemia was the most frequent diagnosis (74%). At CBT, 40 patients had early, 70 intermediate, and 37 advanced disease. CB grafts contained a median of 4.1 × 10(7)/kg total nucleated cells (TNCs) after thawing. The cumulative incidence (CI) of neutrophil recovery was 90% at day +60. CIs of acute and chronic graft-versus-host disease (GVHD) were 12% and 10% at 2 years, respectively. At 5 years, CIs of nonrelapse mortality and relapse were 9% and 47%, respectively; the probability of disease-free survival (DFS) and overall survival were 44% and 55%, respectively. Among other factors, higher TNCs infused was associated with rapid neutrophil recovery and improved DFS. The use of methotrexate as GVHD prophylaxis decreased the CI of engraftment. Patients without advanced disease had improved DFS. These results support banking and use of CB units for RCBT. Cell dose, GVHD prophylaxis not including methotrexate, and disease status are important factors for outcomes after RCBT.
Collapse
|